Key information

🔎 Fund Overview

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The Company's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.